Skip to main content

atrasentan

Generic: ATRASENTAN HYDROCHLORIDE·Brand: VANRAFIA, Vanrafia

atrasentan: developed by 2 companies · 3 clinical trials tracked · 1 FDA decision.

atrasentan evidence translation

What we can confirm

1 FDA record · 3 tracked trials

What it means

More than one developer is source-backed. Until you choose one, AI stays drug-only and does not guess ownership.

What to watch

Watch active trials and any change in FDA or trial status.
BioSniper AIPage evidence connected

Prepared research question

What is verified about atrasentan, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence5 indications · 0 study sponsors

Related indications

IgA nephropathy (IgAN) and proteinuric glomerular diseasesAlport SyndromeDiabetic Kidney DiseaseFocal Segmental GlomerulosclerosisIgA Nephropathy

Study sponsors

No additional listed-company sponsor is linked.

Development Pipeline (2)
CompanyPhase
CHINOOK THERAPEUTICS, INC. (KDNY)
IgA nephropathy (IgAN) and proteinuric glomerular diseases
Phase 3
Novartis AG (NVS)Approved
Clinical Trials (3)

A Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy on Sodium-glucose Cotransporter-2 Inhibitors (SGLT2i)

NCT05834738·Phase 2·NVS
Completed

Primary endpoint: Percentage Change in Proteinuria (UPCR From a 24-Hour Urine Collection) From Baseline to Week 12

InterventionalRandomizedtriple54 enrolledStarted 2023-07Completion 2025-1030 sites · Australia, Brazil, Malaysia, South Korea…Novartis Pharmaceuticals

A Phase 2, Open-Label, Basket Study of Atrasentan in Patients With Proteinuric Glomerular Diseases

NCT04573920·Phase 2·NVS
Active, not recruiting

Primary endpoint: Change in proteinuria for IgAN, FSGS, and Alport syndrome patients receiving 0.75 mg atrasentan QD

Interventionalopen103 targetStarted 2021-03Completion 2026-1033 sites · Australia, Italy, South Korea, Spain…Novartis Pharmaceuticals

A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients With IgA Nephropathy at Risk of Progressive Loss of Renal Function

NCT04573478·Phase 3·NVS
Active, not recruiting

Primary endpoint: Double-blind period: Change in proteinuria

InterventionalRandomizeddouble404 targetStarted 2020-12Completion 2028-0450 sites · Argentina, Australia, Brazil, Canada…Novartis Pharmaceuticals
FDA Decisions1 records
Approval(NVS)FDA ↗
NDA219208Type 1 - New Molecular EntityStandardOralTablet

Frequently asked questions

Who is developing atrasentan?

atrasentan is being developed by CHINOOK THERAPEUTICS, INC., Novartis AG.

How many clinical trials involve atrasentan?

BioSniper tracks 3 clinical trials involving atrasentan.

What is atrasentan's latest FDA decision?

The most recent tracked FDA decision for atrasentan is Approval, dated April 2, 2025.